AstraZeneca PLC





Market Closed - London Stock Exchange 11:35:11 2023-12-06 am EST Intraday chart for AstraZeneca PLC 5-day change 1st Jan Change
10,130 GBX -0.14% +0.98% -9.70%
This article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
AstraZeneca's Koselugo Now Available in Malaysia for Pneumiatric Patients with Symptomatic Neurofibromatosis Type 1plexiform Neurofibromas CI
Altimmune open to partnerships, deals with drugmakers, says CEO RE
Anything is possible
JPMorgan Trims AstraZeneca PT, Affirms Overweight Rating MT
Analyst recommendations: Broadcom, Deere & Co, Rio Tinto, Lululemon, Nike...
Goldman lifts Landsec and British Land AN
Wuxi Bio Selloff Extends as Analysts Cut Forecasts DJ
ASTRAZENECA : Gets a Buy rating from JP Morgan ZD
Roche enters obesity drugs race with $2.7 bln Carmot deal RE
GLOBAL MARKETS LIVE : Roche, Uber, Amazon, Spotify, 888...
AstraZeneca: AI collaboration with Absci CF
Model N: A niche positioning
Absci Shares Rise 27% After Announcing Collaboration With AstraZeneca DJ
Sector Update: Health Care Stocks Lean Lower Pre-Bell Monday MT
Sector Update: Health Care MT
Absci Working With AstraZeneca to Use AI Platform to Discover Oncology Candidate MT
Absci Corporation Announces Collaboration with Astrazeneca to Advance Ai-Driven Oncology Candidate CI
UK Stocks-Factors to watch on Dec 4 RE
Roche enters obesity drug market with $2.7 bln Carmot deal RE
AstraZeneca, Absci Enter $247 Million Partnership to Develop New Cancer Treatment MT
AstraZeneca, AI biologics firm Absci tie up on cancer drug - FT RE
AstraZeneca ties up with AI biologics company to develop cancer drug - FT RE
US obesity docs expect Lilly weight-loss drug to show similar heart benefit as Wegovy RE
Global markets live: Meta, Tesla, BP Plc, Pfizer, General Motors...
Sector Update: Health Care Stocks Steady Pre-Bell Friday MT
Chart AstraZeneca PLC
More charts
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (96.9%). Net sales break down by treatment area between oncology (34%), cardiovascular, renal and metabolic diseases (21.4%), respiratory and autoimmune diseases (13.4%), and other (31.2%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (3.1%). Net sales are distributed geographically as follows: the United Kingdom (7%), Europe (20.1%), Americas (44.2%) and Africa/Asia/Australia (28.7%).
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
More Ratings
Mean consensus
Number of Analysts
Last Close Price
Average target price
Spread / Average Target
1st Jan change Capi.
-9.70% 198 B $
+61.62% 529 B $
+44.67% 444 B $
-11.25% 382 B $
-4.75% 269 B $
-9.29% 255 B $
+1.56% 200 B $
-43.64% 164 B $
+2.94% 145 B $
-4.13% 117 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock AstraZeneca PLC - London Stock Exchange
  4. News AstraZeneca PLC
  5. AstraZeneca Completes $1 Billion Purchase of Pfizer's Rare Disease Gene Therapy Portfolio
The best tools reserved for subscribers to boost the performance of your investments!
Optimize my profits